Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.
JHEP Rep
; 3(6): 100361, 2021 Dec.
Article
en En
| MEDLINE
| ID: mdl-34661089
AE, adverse event; ALT, alanine aminotransferase; Anti-HBs, hepatitis B surface antibody; BMI, body mass index; BRII-179; CHB; CHB, chronic hepatitis B; ELISpot, enzyme-linked immune absorbent spot; HBV, hepatitis B virus; HBV-specific immune response; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; IFN-alpha; IFN-α, interferon-α; IM, intramuscular; IU, international units; NA, nucleos(t)ide analogue; PBMCs, peripheral blood mononuclear cells; PEG-IFN-α, pegylated interferon-α; SAE, serious adverse events; Th1, T helper type 1; immunotherapy
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
JHEP Rep
Año:
2021
Tipo del documento:
Article
País de afiliación:
Singapur